SCHEMBL12377086

SCHEMBL12377086

CCCOc1cccc(/C=C/CNC)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR4 O00206 3/20 0.50
TLR2 O60603 3/20 0.50
ALDH1A1 P00352 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
KDM4E B2RXH2 1/20 0.43
KMT2A Q03164 1/20 0.43
NPSR1 Q6W5P4 1/20 0.41
CHRNA7 P36544 1/20 0.40
NAMPT P43490 1/20 0.39
LMNA P02545 2/20 0.39
CHRM2 P08172 1/20 0.39
CHRM1 P11229 1/20 0.39
CHRM3 P20309 1/20 0.39
NFE2L2 Q16236 2/20 0.39
LCK P06239 1/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
TSHR P16473 1/20 0.38
MAOA P21397 2/20 0.38
MAOB P27338 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8986180 0.87 TLR4 (0.43) TLR4TLR2ALDH1A1SMN1; SMN2KDM4E
SCHEMBL73717 0.84 TLR4 (0.55) TLR4TLR2ALDH1A1SMN1; SMN2KDM4E
SCHEMBL12377088 0.81 PTGS1 (0.51) KMT2ANPSR1LMNANPC1RAB9A
SCHEMBL10475476 0.81 NFE2L2 (0.58) CHRM2CHRM1CHRM3NFE2L2
SCHEMBL7541618 0.80 LCK (0.58) TLR4TLR2ALDH1A1SMN1; SMN2KDM4E
SCHEMBL7541623 0.80 LCK (0.58) TLR4TLR2ALDH1A1SMN1; SMN2KDM4E
Dimethylamine SCHEMBL4375978 0.77 TLR4 (0.47) TLR4TLR2ALDH1A1SMN1; SMN2KDM4E
SCHEMBL11563909 0.77 TSHR (0.51) TLR4TLR2KMT2ATSHRNR1H4
SCHEMBL59487 0.76 KMT2A (0.51) TLR4TLR2ALDH1A1SMN1; SMN2KDM4E
SCHEMBL6339806 0.76 CCNB2 (0.62) TLR4TLR2ALDH1A1SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8008440-B2 Combinatorial synthesis of libraries of macrocyclic compounds useful in drug discovery TRANZYME PHARMA INC. (CA) 2011-08-30 US disclosed
US-20070117154-A1 Cyclic lactams comprising three amino acids and a tether chain to control the overall shape of the macromolecule; beta-turn mimetics to explore conformationally restricted structures; proteolytic enzyme resistance (nonhydrolyzing); cell penetration; anticoagulants; anticarcinogenic agents MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED (IE) 2007-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070117154-A1 Cyclic lactams comprising three amino acids and a tether chain to control the overall shape of the macromolecule; beta-turn mimetics to explore conformationally restricted structures; proteolytic enzyme resistance (nonhydrolyzing); cell penetration; anticoagulants; anticarcinogenic agents F2, BCAT1, DAO TLR4 3090/4885TLR2 2491/4885ALDH1A1 3793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.